HANXBIO-B (03378) Sets 27 March 2026 Board Meeting to Review FY2025 Results and Final Dividend Proposal

Bulletin Express

Mar 17

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B, 03378) has scheduled a board meeting for Friday, 27 March 2026. Directors will review and approve the consolidated annual results for the year ended 31 December 2025 and decide whether to recommend a final dividend for shareholders.

The meeting will also authorize the public release of the FY2025 results following board approval.

Board composition as of the announcement date (17 March 2026): • Executive Directors: Dr. Zhang Faming (Chairman), Dr. Henry Qixiang Li, Mr. Liu Min, and Ms. Xiao Jieyu • Non-executive Director: Dr. Li Jian • Independent Non-executive Directors: Dr. Bi Honggang, Mr. Chen Qifeng, Mr. Wong Sai Hung, and Dr. Zhang Qiongguang

The company provided no further financial metrics or dividend details in the notice.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1168661413"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1168661413\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1168661413?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-17 17:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168661413","market":"hk","top_or_hot":-1,"title":"HANXBIO-B (03378) Sets 27 March 2026 Board Meeting to Review FY2025 Results and Final Dividend Proposal","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B, 03378) has scheduled a board meeting for Friday, 27 March 2026. Directors will review and approve the consolidated annual results for the year ended 31 December 2025 and decide whether to recommend a final dividend for shareholders.</p>\n<p>The meeting will also authorize the public release of the FY2025 results following board approval.</p>\n<p>Board composition as of the announcement date (17 March 2026):\n• Executive Directors: Dr. Zhang Faming (Chairman), Dr. Henry Qixiang Li, Mr. Liu Min, and Ms. Xiao Jieyu  \n• Non-executive Director: Dr. Li Jian  \n• Independent Non-executive Directors: Dr. Bi Honggang, Mr. Chen Qifeng, Mr. Wong Sai Hung, and Dr. Zhang Qiongguang</p>\n<p>The company provided no further financial metrics or dividend details in the notice.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HANXBIO-B (03378) Sets 27 March 2026 Board Meeting to Review FY2025 Results and Final Dividend Proposal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHANXBIO-B (03378) Sets 27 March 2026 Board Meeting to Review FY2025 Results and Final Dividend Proposal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-17 17:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B, 03378) has scheduled a board meeting for Friday, 27 March 2026. Directors will review and approve the consolidated annual results for the year ended 31 December 2025 and decide whether to recommend a final dividend for shareholders.</p>\n<p>The meeting will also authorize the public release of the FY2025 results following board approval.</p>\n<p>Board composition as of the announcement date (17 March 2026):\n• Executive Directors: Dr. Zhang Faming (Chairman), Dr. Henry Qixiang Li, Mr. Liu Min, and Ms. Xiao Jieyu  \n• Non-executive Director: Dr. Li Jian  \n• Independent Non-executive Directors: Dr. Bi Honggang, Mr. Chen Qifeng, Mr. Wong Sai Hung, and Dr. Zhang Qiongguang</p>\n<p>The company provided no further financial metrics or dividend details in the notice.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1168661413","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168661413","pubTimestamp":1773739399,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B, 03378) has scheduled a board meeting for Friday, 27 March 2026. Directors will review and approve the consolidated annual results for the year...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"汉思生物-B(03378)定于2026年3月27日召开董事会会议，审阅2025财年业绩及末期股息建议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B, 03378) has scheduled a board meeting for Friday, 27 March 2026. Directors will review and approve the consolidated annual results for the year ended 31 December 2025 and decide whether to recommend a final dividend for shareholders.\nThe meeting will also authorize the public release of the FY2025 results following board approval.\nBoard composition as of the announcement date (17 March 2026):\n• Executive Directors: Dr. Zhang Faming (Chairman), Dr. Henry Qixiang Li, Mr. Liu Min, and Ms. Xiao Jieyu  \n• Non-executive Director: Dr. Li Jian  \n• Independent Non-executive Directors: Dr. Bi Honggang, Mr. Chen Qifeng, Mr. Wong Sai Hung, and Dr. Zhang Qiongguang\nThe company provided no further financial metrics or dividend details in the notice.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences,SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}